MISSION TO RAISE AWARENESS OF SARCOMA AND CLINICAL TRIAL FUNDING Research lagging for sarcoma, despite accounting for one third of adolescent cancer deaths
With
Associate Professor Jeremy Lewin, Medical Oncologist,
Peter MacCallum Cancer Centre & Medical Director,
Victorian Adolescent and Young Adult Cancer Service &
Research & Education Lead – Sarcoma, VCCC Alliance
Dr Vivek Bhadri,
Paediatric and Adolescent Medical Oncologist
Chris O’Brien Lifehouse & Westmead Public Hospital &
Board Director
Australia and New Zealand Sarcoma Association (ANZSA)
AUSTRALIAN HEALTH JOURNAL SEGMENT
Filmed in Sydney & Melbourne | September 2025
Sarcoma, a rare and aggressive cancer, remains the deadliest cancer for children and young adults, accounting for nearly one third (30%) of cancer-related deaths among those aged 15–24 and one tenth (10%) of those aged 0–14. Further, still severely under-diagnosed, sarcoma only accounts for one sixth (15%) of all cancer diagnoses in the 15 – 24 age group, and less than a tenth (8%) among children under 10.
Despite this, public awareness and research funding for sarcoma funding remain critically low, with sarcoma receiving just $4.6m in funding for research in 2018-2020 – compared to the tens of millions other cancers receive. Sarcoma gets only a tiny fraction of funding for research that more common cancers receive, despite having the same costs to conduct studies.
The lack of funding reflects long-term survival rates for sarcoma which remain concerningly low, at just a 50% 10-year survival rate, while five-year survival rates for common cancers such as prostate and breast cancer have increased to over 90% in the past four decades (96% and 92% respectively).
Accounting for just 1% of all adult cancer diagnoses, sarcomas are rare and complex cancers that form in bone, cartilage or soft tissue8. There are over 100 different subtypes of sarcoma, which each require their own diagnostic and treatment pathways, which is why continued research is essential to improving patient outcomes.
Research indicates sarcomas are misdiagnosed in nearly one third (30%) of cases, emphasising the importance of ongoing research to support diagnostic developments, alongside improvements in patient treatment and management pathways.
Source: Australian and New Zealand Sarcoma Association (ANZSA) media release 1 July 2025
-
HIGHLIGHTS The power of social determinants of health, panel discussion
Clinicians and consumers know only too well that life circumstances such as poor housing, income and food insecurity can have a negative impact on health outcomes. Conversely, participation in community activities, social connection and access to nature parks and leisure facilities can help maintain health and wellbeing.
More recent phenomena in public health have also focused us on the health and social care connection. Stress factors such as the sudden loss of employment and social interaction, moving to remote work or schooling, and the impacts of sudden, localised COVID-19 ‘lockdowns’ to prevent further outbreaks were triggers of increased psychological distress.
And loneliness is being described as our latest epidemic with chronic loneliness inked to a myriad of health problems and earlier death. A recent report found one in four Australians say they feel persistently lonely, and that loneliness costs $2.7 bn a year in health costs alone.
-
Victorian social prescribing program underway
n Part 2 of the Models of Care on Social Prescribing, Australian Health Journal spoke to 4 people involved in the Connect Local program under the Connecting Communities to Care 4 year program. The free program for over 65’s promotes wellbeing through social connection and is underway in the Glen Eira community in Melbourne.
– Deidre McGill, Executive General Manager, At Home Support, Bolton Clarke
– Ann Van Leerdam, Connect Local Community Connector, Bolton Clarke
– Dr Rajna Ogrin, Senior Research Fellow, Bolton Clarke Research Institute, Bolton Clarke - Dr Daniel Fineberg, Deputy Director General Medicine, Alfred Hospital, Victoria -
CASE STUDY: Evolution in the medical device supply chain
For Cardinal Health, a global manufacturer and distributor of medical products, the process begins when products arrive in Australia and are cleared by customs before being stored at their Sydney warehouse. From here, they fulfil orders for various clients, including hospitals and wholesalers, supported by DHL’s logistics services.
